Allogeneic Stem Cell Transplantation Using AlphaBeta T Cell and CD19 B Cell Depletion for Children, Adolescents, and Young Adults with Malignant and Non-malignant Blood Diseases

What this Trial Is About

This research aims to study children, adolescents, and young adults up to 30 years old who have malignant or non-malignant blood disorders and are undergoing allogeneic stem cell transplantation AlloSCT. The trial focuses on selecting stem cells using alphabeta T cell and CD19 B cell depletion techniques. The purpose is to evaluate outcomes related to this specialized cell selection method in these patients. Participants will receive conditioning treatment before transplantation that may be full intensity, reduced intensity, or reduced toxicity based on their disease, status, organ function, and performance. They will then undergo AlloSCT with stem cells processed using alphabeta CD3CD19 cell depletion via the Prodigy system. Standard pre-conditioning and post-transplant monitoring will be provided throughout the study. During the study, participants will be monitored for engraftment success, immune system recovery, graft-versus-host disease GVHD, and quality of life. Researchers will track adverse events related to the cell-depleted stem cell administration over one year. The total involvement includes regular evaluations and follow-up to assess treatment effects and safety over a 12-month period.

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion